Source: CureToday articles
The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.
Recent Content
- Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma
- Carvykti Effective for R/R Multiple Myeloma in Real-World Setting
- BRCA variants increase risk for multiple myeloma, particularly at younger age
- Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma
- Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
- Dexamethasone benefits in multiple myeloma ‘fade into oblivion’ after a couple months
- Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity
- Maintenance combination extends PFS in newly diagnosed multiple myeloma
- Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma
- myeloMATCH to use genomics to enroll patients into target-based leukemia trials